Beta Bionics (NASDAQ:BBNX) Price Target Raised to $28.00

Beta Bionics (NASDAQ:BBNX) had its price objective upped by Truist Financial from $23.00 to $28.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also recently weighed in on the stock. William Blair assumed coverage on shares of Beta Bionics in a research note on Friday, August 21st. They set a “market perform” rating for the company. UBS Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a research note on Tuesday, September 15th. Wells Fargo & Company started coverage on Beta Bionics in a report on Wednesday. They set an “overweight” rating and a $28.00 target price on the stock. Leerink Partners increased their target price on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, September 14th. Finally, The Goldman Sachs Group raised their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.91.

Beta Bionics Stock Down 1.1%

Beta Bionics stock opened at $21.51 on Thursday. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The firm’s 50-day simple moving average is $18.17 and its 200 day simple moving average is $14.42. The firm has a market capitalization of $967.73 million, a PE ratio of -13.04 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, research analysts expect that Beta Bionics will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Stephen Feider sold 6,675 shares of Beta Bionics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the sale, the chief financial officer owned 159,378 shares of the company’s stock, valued at $3,045,713.58. The trade was a 4.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 6,430 shares of Beta Bionics stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total value of $147,890.00. Following the completion of the sale, the director directly owned 19,564 shares of the company’s stock, valued at approximately $449,972. This represents a 24.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,223 shares of company stock worth $1,983,398 in the last three months. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Beta Bionics

Hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new position in shares of Beta Bionics during the 2nd quarter worth about $2,524,000. Bank of America Corp DE purchased a new stake in Beta Bionics in the second quarter valued at approximately $8,566,000. Man Group plc acquired a new position in Beta Bionics during the second quarter worth approximately $419,000. Legal & General Group Plc acquired a new position in Beta Bionics during the second quarter worth approximately $62,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Beta Bionics during the second quarter worth approximately $172,000.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Truist Financial raised its price target on Beta Bionics to $28 from $23 and maintained a “Buy” rating, implying meaningful upside from recent trading levels. Wells Fargo also initiated coverage with an “Overweight” rating and a $28 target, while other analysts have recently raised their targets. Truist Financial rating
• Neutral Sentiment: Multiple law firms publicized a securities class action against Beta Bionics on behalf of investors who purchased shares between July 30, 2025, and February 24, 2026. The lead-plaintiff deadline is November 3, 2026; the repeated notices are mostly informational but increase attention on the company’s legal situation. Kaplan Fox class action notice
• Negative Sentiment: The lawsuits allege that Beta Bionics failed to adequately disclose FDA concerns, including a 2025 Form 483 and more than 18,000 iLet-related complaints. The allegations link later disclosures about FDA compliance and device safety to a sharp share-price decline. They have not been proven, but could create financial, operational and reputational uncertainty. BFA Law BBNX investor alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her position by about 24.7%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but it nevertheless adds to investor caution. SEC insider sale filing

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.